Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1183/09031936.00201612 http://scihub22266oqcxt.onion/10.1183/09031936.00201612 23397304!ä!23397304 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\23397304.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Eur+Respir+J 2013 ; 41 (4): 985-90 Nephropedia Template TP {{tp|p=23397304|t=2013. Chronic thromboembolic pulmonary hypertension: role of medical therapy |pdf=|usr=}}{{23397304}} gab.com Text Chronic thromboembolic pulmonary hypertension: role of medical therapy JO: Eur Respir J http://www.kidney.de/pget.php?&tw=1&pmid=23397304 #FOAvip Chronic thromboembolic pulmonary hypertension (CTEPH) is a progressive disease with poor prognosis if not treated. The treatment of choice is surgery with pulmonary endarterectomy. However, a significant percentage of patients are deemed non-operable due to distal distribution of the disease and arteriopathy in the non-occluded areas that is indistinguishable from pulmonary arterial hypertension (PAH). The overlap in clinical presentation, pathological features and pathogenesis between PAH and CTEPH provides a compelling rationale for exploring the efficacy of PAH-targeted therapies in CTEPH. These therapies are often considered for non-operable patients and are also used in operable patients as a bridge to surgery or as post-pulmonary endarterectomy therapy for persistent pulmonary hypertension, despite the fact they are not licensed for CTEPH. Two randomised clinical trials have been performed in non-operable CTEPH patients. The BENEFiT study, with the endothelin receptor antagonist bosentan, did not show improvement in walking distance. Recently, the CHEST-1 trial, with the soluble guanylate cyclase stimulator riociguat, met study end-point and demonstrated significant improvement in walking distance in patients with non-operable CTEPH. There is an urgent need for more randomised clinical trials designed to clarify whether administration of PAH-targeted therapies improves clinically meaningful end-points in various CTEPH populations. Twit Text FOAVip Chronic thromboembolic pulmonary hypertension: role of medical therapy ????Eur Respir J http://www.kidney.de/pget.php?&tw=1&pmid=23397304 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=23397304 #FOAvip English Wikipedia <ref>{{Cite pmid|23397304}}</ref> Chronic thromboembolic pulmonary hypertension: role of medical therapy #MMPMID23397304 Pepke-Zaba J; Jansa P; Kim NH; Naeije R; Simonneau G Eur Respir J 2013[Apr]; 41 (4): 985-90 PMID23397304show ga Chronic thromboembolic pulmonary hypertension (CTEPH) is a progressive disease with poor prognosis if not treated. The treatment of choice is surgery with pulmonary endarterectomy. However, a significant percentage of patients are deemed non-operable due to distal distribution of the disease and arteriopathy in the non-occluded areas that is indistinguishable from pulmonary arterial hypertension (PAH). The overlap in clinical presentation, pathological features and pathogenesis between PAH and CTEPH provides a compelling rationale for exploring the efficacy of PAH-targeted therapies in CTEPH. These therapies are often considered for non-operable patients and are also used in operable patients as a bridge to surgery or as post-pulmonary endarterectomy therapy for persistent pulmonary hypertension, despite the fact they are not licensed for CTEPH. Two randomised clinical trials have been performed in non-operable CTEPH patients. The BENEFiT study, with the endothelin receptor antagonist bosentan, did not show improvement in walking distance. Recently, the CHEST-1 trial, with the soluble guanylate cyclase stimulator riociguat, met study end-point and demonstrated significant improvement in walking distance in patients with non-operable CTEPH. There is an urgent need for more randomised clinical trials designed to clarify whether administration of PAH-targeted therapies improves clinically meaningful end-points in various CTEPH populations. |Anticoagulants/therapeutic use[MESH] |Chronic Disease[MESH] |Diagnosis, Differential[MESH] |Disease Progression[MESH] |Endarterectomy[MESH] |Endothelin Receptor Antagonists[MESH] |Familial Primary Pulmonary Hypertension[MESH] |Humans[MESH] |Hypertension, Pulmonary/diagnosis/*therapy[MESH] |Phosphodiesterase Inhibitors/therapeutic use[MESH] |Prognosis[MESH] |Prostaglandins/therapeutic use[MESH] |Randomized Controlled Trials as Topic[MESH] |Thromboembolism/diagnosis/*therapy[MESH]Chronic thromboembolic pulmonary hypertension: role of medical therapy(epmc).pdf DeepDyve Pubget Overpricing